The US FDA has granted orphan drug designation for Oasmia Pharmaceutical's Paclical (paclitaxel) for the treatment of ovarian cancer. The Swedish company hopes to achieve a 35% market share, its CEO, Julian Aleksov, told Scrip.
Oasmia presses ahead with new water-soluble paclitaxel formulation
The US FDA has granted orphan drug designation for Oasmia Pharmaceutical's Paclical (paclitaxel) for the treatment of ovarian cancer. The Swedish company hopes to achieve a 35% market share, its CEO, Julian Aleksov, told Scrip.
More from Anticancer
More from Therapeutic Category
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.